Learn how these three leading Hemonc experts are using RainDance Technologies products in their research today: Dr. Eric Padron of Moffitt Cancer Center, Dr. Torsten Haferlach of Munich Leukemia Laboratory, and Dr. Catherine Smith of University of California, San Francisco. Want more
Abstract Targeted next-generation sequencing has become a critical tool for the interrogation of genomic events in myeloid malignancies. In this webinar, Dr. Eric Padron of the Moffitt Cancer Center, discussed his experience using the RainDance ThunderBolts Myeloid panel focusing on h
Hematologic oncology research experts to present ThunderBolts Myeloid Panel performance data at American Association for Cancer Research (AACR) Annual Meeting BILLERICA, Mass. — April 20, 2015 — RainDance Technologies, Inc., a genomics tools company simplifying the analysis of complex
RainDance Technologies® is making complex genetics simple. The company’s ultra-sensitive genomic tools enable research of novel non-invasive liquid biopsy applications that should result in more accurate, reliable, cost-effective, and early detection of cancer and other inherited and infectious diseases. Major research institutions and laboratories around the world rely on the performance of RainDance systems. Based outside Boston, Massachusetts, the company supports customers using RainDrop® Digital PCR, as well as the ThunderStorm® and ThunderBolts™ Next-Generation Sequencing Enrichment Systems through its international sales and service operations, as well as a global network of distributors and commercial service providers. Both technology platforms have been recognized by The Scientist as Top 10 Innovations with the RainDrop System winning the award in 2014 and the ThunderStorm System winning the award in 2011.